Making clinical trials more comparable, consistent, and focused on the biological mechanisms underlying the onset and development of multiple sclerosis (MS) are all key to more quickly realizing new treatments for progressive MS, according to the International Progressive MS Alliance. To attain these goals, the Alliance, a worldwide collaborative organization committed to the speedy development of new therapies for progressive forms of MS, published a series of recommendations on how early MS trials should be…

You must be logged in to read/download the full post.